SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Insmed Inc. (INSM) -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (45)3/27/2003 6:00:00 PM
From: mopgcw  Respond to of 136
 
Wilder,

Most appreciated. I think your analysis is pretty fair. Ctrx and now insm has generally been a long shot play buying in for cents for somatokine upside. i have been encouraged that they keep making positive progress in diabetes, although as you note, they have been very small studies. They have a big chunk of cash to burn through to see further diabetes results and GHIS.

thanks



To: keokalani'nui who wrote (45)5/29/2003 7:54:52 PM
From: mopgcw  Read Replies (1) | Respond to of 136
 
Has had a nice run from 40 cents. I took profits here at $2, to wash off the disaster from INS-1.

What do you think of the ASCO stuff? Seems like a long ways away...

thanks.

george


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News